Kane Biotech (CVE:KNE) Releases Quarterly Earnings Results

Kane Biotech (CVE:KNE) released its quarterly earnings results on Thursday. The company reported C($0.01) EPS for the quarter, reports. The company had revenue of C$0.05 million during the quarter.

Kane Biotech Stock Performance

Kane Biotech stock opened at C$0.13 on Friday. The company has a current ratio of 0.34, a quick ratio of 0.39 and a debt-to-equity ratio of 1,164.24. The company has a market cap of C$17.14 million, a PE ratio of -4.33 and a beta of 0.55. The company’s 50-day moving average is C$0.13 and its two-hundred day moving average is C$0.10. Kane Biotech has a 1 year low of C$0.05 and a 1 year high of C$0.17.

Insider Buying and Selling at Kane Biotech

In other news, Director Philip Renaud sold 2,000,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of C$0.13, for a total value of C$260,000.00. Insiders own 34.93% of the company’s stock.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.